New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
09:03 EDTSGEN, TKPYYSeattle Genetics to receive milestone payments from Takeda on Adcetris
Seattle Genetics (SGEN) announced that it will receive milestone payments from Takeda (TKPYY) totaling $6M as a result of achieving the first commercial sale of ADCETRIS in three key countries in Takeda’s territories outside of the European Union and Japan, consisting of Australia, South Korea and Mexico. All three countries have permission to sell commercial product from their local health authority for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma and systemic anaplastic large cell lymphoma. In addition to these three countries, ADCETRIS is also commercially available in the U.S., European Union, Japan, Canada, Ukraine, Switzerland, Singapore, Norway, Liechtenstein and Iceland. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL and known to be expressed in some types of non-Hodgkin lymphoma, including sALCL.
News For SGEN;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
06:16 EDTTKPYYTakeda offers $2.2B to resolve Actos lawsuits, Bloomberg says
Takeda has offered $2.2B to settle allegations of concealing the potential risks of its Actos diabetes drug, reports Bloomberg, citing three people familiar with the matter. The settlement proposes to cover over 8,000 U.S. lawsuits with an average payout of $275,000 per case, though the sources said the company could choose to settle only some of the cases and fight others. There is some opposition from lawyers who contend that $275,000 is not enough to compensate users of the drug who developed bladder cancer, added the sources. Reference Link
March 31, 2015
09:32 EDTTKPYYInfinity to buy out future royalty obligations to Takeda for duvelisib sales
Subscribe for More Information
March 27, 2015
06:32 EDTSGENAtara Biotherapeutics appoints Eric Dobmeier to board
Atara Biotherapeutics (ATRA) announced that Eric Dobmeier has joined its board. Dobmeier is currently the COO of Seattle Genetics (SGEN).
March 23, 2015
12:17 EDTTKPYYOn The Fly: Midday Wrap
Subscribe for More Information
08:22 EDTSGENEditorial on Seattle Genetics AETHERA was positive, says RBC Capital
RBC Capital believes that the Lancet editorial on Seattle Genetics' AETHERA was positive, and the firm expects the drug's label to expand. However, the firm warns that for further upside Seattle Genetics needs one or more programs targeting unmet need with clearly delineated paths to approval. The firm keeps a $50 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use